$30 million financing has Bluebird Bio whistling a happy tune
This article was originally published in Scrip
Executive Summary
Bluebird Bio this week was whistling to the tune of $30 million, which the Cambridge, Massachusetts-based biotech raised in a venture capital round to advance its gene therapies aimed at treating severe genetic disorders.